Jeff Yass’s Oramed Pharmaceuticals ORMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $78.9K | Buy |
+16,900
| New | +$76.4K | ﹤0.01% | 12689 |
|
|
2025
Q3 | – | Sell |
-23,400
| Closed | -$52.6K | – | 13487 |
|
|
2025
Q2 | $52.6K | Buy |
+23,400
| New | +$51.6K | ﹤0.01% | 12094 |
|
|
2024
Q1 | – | Sell |
-19,700
| Closed | -$45.5K | – | 13015 |
|
|
2023
Q4 | $45.5K | Buy |
+19,700
| New | +$42.1K | ﹤0.01% | 11747 |
|
|
2023
Q1 | – | Sell |
-112,500
| Closed | -$1.35M | – | 13220 |
|
|
2022
Q4 | $1.35M | Buy |
112,500
+92,100
| +451% | +$716K | ﹤0.01% | 5509 |
|
|
2022
Q3 | $132K | Sell |
20,400
-17,600
| -46% | -$142K | ﹤0.01% | 11408 |
|
|
2022
Q2 | $174K | Sell |
38,000
-31,700
| -45% | -$169K | ﹤0.01% | 10842 |
|
|
2022
Q1 | $603K | Buy |
69,700
+2,500
| +4% | +$25.6K | ﹤0.01% | 8477 |
|
|
2021
Q4 | $960K | Sell |
67,200
-108,100
| -62% | -$2.26M | ﹤0.01% | 7407 |
|
|
2021
Q3 | $3.85M | Buy |
175,300
+98,000
| +127% | +$1.67M | ﹤0.01% | 4430 |
|
|
2021
Q2 | $1.03M | Buy |
77,300
+9,400
| +14% | +$108K | ﹤0.01% | 7674 |
|
|
2021
Q1 | $690K | Buy |
67,900
+38,500
| +131% | +$316K | ﹤0.01% | 8701 |
|
|
2020
Q4 | $125K | Buy |
29,400
+6,000
| +26% | +$19.5K | ﹤0.01% | 10371 |
|
|
2020
Q3 | $61K | Sell |
23,400
-24,400
| -51% | -$85K | ﹤0.01% | 10147 |
|
|
2020
Q2 | $169K | Sell |
47,800
-6,500
| -12% | -$21.8K | ﹤0.01% | 9175 |
|
|
2020
Q1 | $165K | Buy |
54,300
+7,600
| +16% | +$33.3K | ﹤0.01% | 8902 |
|
|
2019
Q4 | $241K | Buy |
+46,700
| New | +$175K | ﹤0.01% | 8424 |
|
|
2016
Q4 | – | Sell |
-73,400
| Closed | -$533K | – | 9970 |
|
|
2016
Q3 | $533K | Sell |
73,400
-35,300
| -32% | -$274K | ﹤0.01% | 5954 |
|
|
2016
Q2 | $907K | Buy |
108,700
+69,000
| +174% | +$588K | ﹤0.01% | 5057 |
|
|
2016
Q1 | $264K | Sell |
39,700
-1,100
| -3% | -$7.36K | ﹤0.01% | 7469 |
|
|
2015
Q4 | $349K | Buy |
40,800
+17,100
| +72% | +$130K | ﹤0.01% | 7421 |
|
|
2015
Q3 | $130K | Sell |
23,700
-9,300
| -28% | -$58.5K | ﹤0.01% | 9011 |
|
|
2015
Q2 | $187K | Buy |
+33,000
| New | +$226K | ﹤0.01% | 9335 |
|
|
2015
Q1 | – | Sell |
-11,000
| Closed | -$50K | – | 9784 |
|
|
2014
Q4 | $50K | Buy |
+11,000
| New | +$72.3K | ﹤0.01% | 9365 |
|
|
2014
Q3 | – | Sell |
-12,200
| Closed | -$117K | – | 9791 |
|
|
2014
Q2 | $117K | Buy |
+12,200
| New | +$125K | ﹤0.01% | 9369 |
|
Other funds holding ORMP
GIA
BCM
Jeff Yass's ORMP Position: Q3 2026 in Review
Jeff Yass sold out of Oramed Pharmaceuticals (ORMP) in Q3 2026, closing a stake of 22,300 shares — an estimated $101K sold.
Jeff Yass first reported a position in ORMP in Q1 2014 and held it in 31 quarters. The position peaked at $2.23M in Q4 2022. 87 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.
- Jeff Yass reported no remaining Oramed Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Jeff Yass sold 22,300 Oramed Pharmaceuticals shares in Q3 2026, an estimated $101K.
- Jeff Yass first reported a position in Oramed Pharmaceuticals in Q1 2014 and held it in 31 quarters.
- Jeff Yass's Oramed Pharmaceuticals position peaked at $2.23M in Q4 2022.
- 87 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.
Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.